Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared ...

In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions ...

Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice? Using an index designed and validated for use in ANCHOR, HRQoL was assessed before random ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A protocol in ...

The distribution of human papillomaviruses (HPVs) must be understood for the control and prevention of cervical cancer. Community-based Papanicolaou and HPV DNA tests were performed on 41 578 women.

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic ...

The Food and Drug Administration approved cemiplimab-rwlc, or Libtayo, from Regeneron (REGN) Pharmaceuticals for the adjuvant treatment of adults ...

Like cervical cancer, anal cancer is often caused by a human papillomavirus and has a premalignant stage called high-grade squamous intraepithelial lesion or anal intraepithelial neoplasia. A ...

Using an index designed and validated for use in ANCHOR, HRQoL was assessed before random assignment (T1), 2-7 days (+3 days) after random assignment/treatment (T2), and 28 days (±7 days) after random ...